Summary of the technology
Modern medicine is currently facing a serious problem of increasing antibiotic resistance of numerous strains of bacteria. It is one of the most serious threats which significantly reduce the effectiveness of treatment of many diseases caused by bacteria.
A particular problem is related to infections evoked by gram-negative bacilli, including the most dangerous strains recognized by the Infectious Diseases Society of America as "alert pathogens." These include the enterococci, methicillin-resistant Staphylococcus aureus (MRSA), Klebisiella, Enterobacter, Pseudomonas aeruginosa and Acinetobacter baumannii.
Therefore, intense research aimed at introducing new antibacterial compounds effective against "alert pathogens” is conducted. Another approach, which part is presented offer, is to increase the effectiveness of existing antibiotics.
Description of the technology
The subject of the offer are new compounds for reduction of the minimum effective dose of antibiotics and drugs used in anticancer therapy. The properties of compounds allow for reducing the minimum inhibitory concentration (MIC) of antibiotics such as doxycycline, nalidixic acid, chloramphenicol and erythromycin
Presented invention includes compounds with properties reducing minimal effective concentration of antibiotics (MIC) by inhibiting the activity of bacterial drug resistance mechanisms. The study showed that offered compounds reduced MIC of the following antibiotics: doxycycline, nalidixic acid, chloramphenicol and erythromycin. The invention also exhibits properties reducing of the minimum effective dose of anticancer drugs. Studies performed in murine lymphoma cells transfected with the human MDR1 gene and colorectal cancer cells have shown that compounds provided in tumor cells increased the retention of dyes - substrates of the main pump of tumor drug resistance ABCB1 (P-gp). Another advantage of the invention is also a synergistic effect with an antineoplastic drug - doxorubicin.
Main advantages of its use
- Properties reducing minimal effective concentration of antibiotics;(reduced MIC) of the following antibiotics: doxycycline, nalidixic acid, chloramphenicol and erythromycin
- Properties reducing of the minimum effective dose of anticancer drugs
- Synergistic effect with an antineoplastic drug - doxorubicin.
- Increase the efficiency of anibiotics and anticancer drugs
About Centre Technology Transfer CITTRU
Technology Transfer Office from PolandCentre Technology Transfer CITTRU
Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted technologies are mainly focused on new materials science, pharmacology and medical technology. Inventions offered by Jagiellonian University are promoted and awarded during numerous exhibitions, e.g. 58th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and services POLLUTEC (Paris 2009).